Prognostic Role of Intragastric Cytopathology and Microbiota in Surgical Patients with Stomach Cancer.
Fluid cytology
gastric cancer
gastric microbiota
gastrointestinal cytology
non-gynecologic cytopathology
Journal
Journal of cytology
ISSN: 0970-9371
Titre abrégé: J Cytol
Pays: India
ID NLM: 8915204
Informations de publication
Date de publication:
Historique:
received:
21
12
2020
accepted:
24
03
2021
entrez:
29
7
2021
pubmed:
30
7
2021
medline:
30
7
2021
Statut:
ppublish
Résumé
In the last decade, analysis of malignant cells and flora in gastric lavage (GL) has provided interesting data on pathogenesis of gastric cancer (GC). For this study, combining such two aspects into one cyto-microbiologic category, we tested the prognostic role of the presence/absence of cancer cells (GL1/GL0) and bacterial microbiota (MB1/MB0) in our GC population. Between April 2012 and August 2019, 79 surgical patients with GC were prospectively investigated with the determination of GL MB. Compared with GL1 MB0, GL1 MB1 strongly correlated with advanced GC, portended poorer overall survival (OS) (45.8 months In the light of our results, the cyto-microbiologic parameter of GL MB should be used to gain a better prognosis of GC patients. Administration of antimicrobial treatment for MB1 subjects should be entertained because it could reduce the risk of oncogenesis.
Sections du résumé
BACKGROUND
BACKGROUND
In the last decade, analysis of malignant cells and flora in gastric lavage (GL) has provided interesting data on pathogenesis of gastric cancer (GC). For this study, combining such two aspects into one cyto-microbiologic category, we tested the prognostic role of the presence/absence of cancer cells (GL1/GL0) and bacterial microbiota (MB1/MB0) in our GC population.
MATERIAL AND METHODS
METHODS
Between April 2012 and August 2019, 79 surgical patients with GC were prospectively investigated with the determination of GL MB.
RESULTS
RESULTS
Compared with GL1 MB0, GL1 MB1 strongly correlated with advanced GC, portended poorer overall survival (OS) (45.8 months
CONCLUSION
CONCLUSIONS
In the light of our results, the cyto-microbiologic parameter of GL MB should be used to gain a better prognosis of GC patients. Administration of antimicrobial treatment for MB1 subjects should be entertained because it could reduce the risk of oncogenesis.
Identifiants
pubmed: 34321774
doi: 10.4103/JOC.JOC_238_20
pii: JCytol-38-82
pmc: PMC8280856
doi:
Types de publication
Journal Article
Langues
eng
Pagination
82-87Informations de copyright
Copyright: © 2021 Journal of Cytology.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Med Hypotheses. 2014 Mar;82(3):403-4
pubmed: 24472868
Sci Rep. 2014 Feb 26;4:4202
pubmed: 24569566
J Invest Surg. 2018 Dec;31(6):546-547
pubmed: 29083937
Anticancer Res. 2019 Aug;39(8):4019-4022
pubmed: 31366483
Cytopathology. 2018 Feb;29(1):41-48
pubmed: 29063636
J Med Microbiol. 2000 Sep;49(9):817-822
pubmed: 10966230
Clujul Med. 2017;90(4):369-376
pubmed: 29151783
Therap Adv Gastroenterol. 2019 Dec 18;12:1756284819894062
pubmed: 31897087
Am Surg. 2011 Jan;77(1):38-43
pubmed: 21396303
Pathol Res Pract. 2018 Sep;214(9):1239-1246
pubmed: 30078471
Anticancer Res. 2017 Aug;37(8):4199-4203
pubmed: 28739707
Rev Esp Enferm Dig. 2016 Sep;108(9):530-40
pubmed: 27604361
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Med Hypotheses. 2016 Sep;94:1-3
pubmed: 27515187
ANZ J Surg. 2019 Jul;89(7-8):E297-E301
pubmed: 31297940
Acta Cytol. 2016;60(2):161-6
pubmed: 27096417
Acta Cytol. 2020;64(6):563-571
pubmed: 32526755
Anticancer Res. 2000 May-Jun;20(3B):2197-201
pubmed: 10928177
Anticancer Res. 2020 Feb;40(2):881-889
pubmed: 32014932
ANZ J Surg. 2001 Oct;71(10):574-6
pubmed: 11552930
Anticancer Res. 2017 Jun;37(6):2817-2821
pubmed: 28551616
Dig Dis Sci. 2020 Mar;65(3):865-873
pubmed: 32040665
Gut. 2018 Feb;67(2):226-236
pubmed: 29102920
Cytopathology. 2008 Jun;19(3):179-84
pubmed: 18495002
Sci Rep. 2019 Sep 19;9(1):13589
pubmed: 31537876
Curr Treat Options Gastroenterol. 2019 Dec;17(4):619-627
pubmed: 31732849
Clinics (Sao Paulo). 2007 Feb;62(1):47-54
pubmed: 17334549
Anticancer Res. 2018 Jan;38(1):433-439
pubmed: 29277806
Anticancer Res. 2013 Oct;33(10):4595-602
pubmed: 24123036
Healthcare (Basel). 2019 Feb 22;7(1):
pubmed: 30813360
Med Hypotheses. 2018 May;114:30-34
pubmed: 29602460
Infect Immun. 2017 Sep 20;85(10):
pubmed: 28694295
Int J Surg. 2013;11(9):1016-21
pubmed: 23747976
Anticancer Res. 2020 Mar;40(3):1691-1695
pubmed: 32132076
Anticancer Res. 2018 Feb;38(2):613-616
pubmed: 29374683
J Invest Surg. 2020 Dec;33(10):932-938
pubmed: 30885025
Anticancer Res. 2019 Feb;39(2):1019-1027
pubmed: 30711990